Pardes Biosciences Inc. (PRDS)
2.18
0.02 (0.93%)
At close: Aug 30, 2023, 7:59 PM
Company Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease.
Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Pardes Biosciences Inc.
| Country | United States |
| IPO Date | Dec 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Thomas G. Wiggans |
Contact Details
Address: 2173 Salk Avenue Carlsbad, California United States | |
| Website | https://www.pardesbio.com |
Stock Details
| Ticker Symbol | PRDS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001822711 |
| CUSIP Number | 69945Q105 |
| ISIN Number | US69945Q1058 |
| Employer ID | 85-2696306 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas G. Wiggans | Chief Executive Officer & Chairman |
| Heidi Henson CPA | Chief Financial Officer |
| Ann D. Kwong Ph.D. | Executive Vice President of Research |
| Brian P. Kearney Pharm.D. | Chief Devel. Officer |
| Dave Kuo | Senior Vice President of HR |
| Dr. Uri A. Lopatin M.D. | Founder & Director |
| Elizabeth Haber Lacy J.D. | Gen. Counsel & Corporation Sec. |
| Patrick O'Brien | Senior Vice President of Investor Relations |
| Sean P. Brusky | Chief Bus. Officer |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 11, 2023 | 15-12G | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | SC 13D/A | [Amend] Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |
| Aug 31, 2023 | 4 | Filing |